You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 22, 2024

TELMISARTAN Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Telmisartan, and when can generic versions of Telmisartan launch?

Telmisartan is a drug marketed by Alembic, Amneal Pharms, Aurobindo Pharma, Cadila Pharms Ltd, Chartwell Rx, Glenmark Pharms Ltd, Hetero Labs Ltd V, Hisun Pharm Hangzhou, Inventia, Jubilant Generics, Mankind Pharma, Micro Labs, Mylan, Prinston Inc, Sandoz, Torrent, Zydus Pharms, Lupin Ltd, Macleods Pharms Ltd, and Natco. and is included in thirty NDAs.

The generic ingredient in TELMISARTAN is hydrochlorothiazide; telmisartan. There are thirty-two drug master file entries for this compound. Ten suppliers are listed for this compound. Additional details are available on the hydrochlorothiazide; telmisartan profile page.

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for TELMISARTAN?
  • What are the global sales for TELMISARTAN?
  • What is Average Wholesale Price for TELMISARTAN?
Drug patent expirations by year for TELMISARTAN
Drug Prices for TELMISARTAN

See drug prices for TELMISARTAN

Drug Sales Revenue Trends for TELMISARTAN

See drug sales revenues for TELMISARTAN

Recent Clinical Trials for TELMISARTAN

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Tyler J CurielEarly Phase 1
THPharm Corp.Phase 1
HK inno.N CorporationPhase 1

See all TELMISARTAN clinical trials

Pharmacology for TELMISARTAN
Paragraph IV (Patent) Challenges for TELMISARTAN
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
MICARDIS Tablets telmisartan 20 mg, 40 mg and 80 mg 020850 1 2006-12-26

US Patents and Regulatory Information for TELMISARTAN

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Aurobindo Pharma TELMISARTAN AND HYDROCHLOROTHIAZIDE hydrochlorothiazide; telmisartan TABLET;ORAL 208727-002 Dec 15, 2016 AB RX No No ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
Prinston Inc TELMISARTAN telmisartan TABLET;ORAL 207882-002 May 3, 2017 AB RX No No ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
Mankind Pharma TELMISARTAN telmisartan TABLET;ORAL 218157-002 Oct 15, 2024 AB RX No No ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
Prinston Inc TELMISARTAN AND HYDROCHLOROTHIAZIDE hydrochlorothiazide; telmisartan TABLET;ORAL 209028-001 Nov 6, 2017 AB RX No No ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

EU/EMA Drug Approvals for TELMISARTAN

Company Drugname Inn Product Number / Indication Status Generic Biosimilar Orphan Marketing Authorisation Marketing Refusal
Boehringer Ingelheim International GmbH Micardis telmisartan EMEA/H/C/000209
HypertensionTreatment of essential hypertension in adults.Cardiovascular preventionReduction of cardiovascular morbidity in patients with:manifest atherothrombotic cardiovascular disease (history of coronary heart disease, stroke, or peripheral arterial disease) or;type-2 diabetes mellitus with documented target-organ damage.
Authorised no no no 1998-12-16
Krka, d.d., Novo mesto  Tolura telmisartan EMEA/H/C/001196
HypertensionTreatment of essential hypertension in adults.Cardiovascular preventionReduction of cardiovascular morbidity in patients with:manifest atherothrombotic cardiovascular disease (history of coronary heart disease or peripheral arterial disease) or;type 2 diabetes mellitus with documented target organ damage.
Authorised yes no no 2010-06-04
Teva B.V. Telmisartan Teva Pharma telmisartan EMEA/H/C/002511
Treatment of essential hypertension in adults.
Authorised yes no no 2011-10-03
Teva B.V. Telmisartan Teva telmisartan EMEA/H/C/001146
Treatment of essential hypertension in adults
Withdrawn yes no no 2010-01-25
>Company >Drugname >Inn >Product Number / Indication >Status >Generic >Biosimilar >Orphan >Marketing Authorisation >Marketing Refusal

TELMISARTAN Market Analysis and Financial Projection Experimental

Telmisartan Market Dynamics and Financial Trajectory

Market Overview

The global telmisartan market is poised for significant growth, driven by several key factors. As of 2023, the market was valued at USD 3,567.30 million and is projected to reach USD 4,661.27 million by 2032, growing at a Compound Annual Growth Rate (CAGR) of 3.4% during the forecast period of 2024-2032[1].

Key Drivers

Increasing Senior Population and Sedentary Lifestyle

The rise in the senior population and the prevalence of sedentary lifestyles are major drivers of the telmisartan market. These factors contribute to an increase in hypertension cases, for which telmisartan is a commonly prescribed medication[1].

Approval of Generic Versions

The approval of abbreviated new drug applications (ANDA) for generic telmisartan tablets has also boosted market growth. Generic versions make the medication more accessible and affordable, increasing its demand[1].

Rising Prevalence of Chronic Renal Disease

An increase in the incidence of chronic renal disease further drives the demand for telmisartan, as it is often prescribed to manage blood pressure in patients with this condition[1].

Healthcare Spending and Awareness

Increased healthcare spending and growing awareness about hypertension treatment are additional drivers. For instance, the National Heart Foundation in Australia has highlighted the importance of better hypertension management, contributing to higher demand for telmisartan[1].

Regional Market Dynamics

North America

North America dominates the global telmisartan market, with an estimated market share of 40.2% in 2024. The region's robust healthcare infrastructure, favorable reimbursement policies, and high prevalence of hypertension contribute to its market leadership[4].

Asia Pacific

The Asia Pacific region is the fastest-growing market for telmisartan, expected to grow at a CAGR of 5.5% during the forecast period. Countries like China and India, with their large patient populations and rising healthcare expenditures, drive this growth. Government initiatives to improve healthcare access and the presence of significant pharmaceutical companies also contribute to the region's rapid expansion[1][3][4].

Market Segments

Hospital Pharmacies

The Hospital Pharmacies segment is expected to generate substantial revenue, growing at a CAGR of 3.5% during the forecast period. This growth is driven by an increase in hypertension patients, the expansion of hospital pharmacies, and improvements in their structure in emerging economies like China and India[1].

Generic and Branded Drugs

The market is also influenced by the shift towards generic drugs. By 2020, around 60% of global telmisartan consumption was fulfilled by generic drug manufacturers, up from 10% prior to the 2012 patent expiration. This shift reflects a preference for more affordable healthcare options[4].

Financial Trajectory

Market Size and Growth

The global telmisartan market is estimated to be valued at USD 4.20 billion in 2024 and is expected to reach USD 5.41 billion by 2031, growing at a CAGR of 3.7% during this period[4].

Revenue and Profit Margins

While the overall consumption and volume sales of telmisartan have increased due to its widespread affordability, the average selling price has declined annually, impacting profit margins. This decline is largely due to the availability of generic substitutes once patents expire[4].

Challenges and Opportunities

Patent Expiration and Generic Substitutes

The expiration of patents for major drugs and the subsequent availability of generic substitutes pose a challenge to the market. However, this also presents an opportunity for companies to capitalize on the growing demand for generic drugs, which are more affordable and increasingly preferred by patients and governments[4].

Emerging Markets and Fixed-Dose Combinations

Emerging markets, particularly in Asia Pacific, offer lucrative opportunities due to their large patient bases and rising healthcare expenditures. Additionally, the demand for fixed-dose combinations that offer enhanced efficacy and adherence is on the rise, providing further growth opportunities for telmisartan market players[4].

Key Players and Competitive Landscape

Major players such as Zydus Cadila, Aurobindo Pharma, Cipla Inc., and Sun Pharmaceutical Industries Ltd. (Ranbaxy Laboratories) are actively contributing to the market's expansion. These companies are focusing on increasing their geographic presence in rising Asia-Pacific nations to capitalize on significant growth potential[1].

Government Policies and Healthcare Infrastructure

Favorable government policies for the prevention and control of hypertension, along with robust healthcare infrastructure in regions like North America, further support market growth. Strategic initiatives by key market players, such as product launches and partnerships with healthcare providers, also fuel market expansion[3][4].

Illustrative Statistics

  • Global Market Size (2023): USD 3,567.30 million[1]
  • Projected Market Size (2032): USD 4,661.27 million[1]
  • CAGR (2024-2032): 3.4%[1]
  • Asia Pacific CAGR: 5.5%[1]
  • North America Market Share: 40.2% in 2024[4]
  • Generic Drug Consumption: 60% of global consumption in 2020[4]

Key Takeaways

  • The global telmisartan market is driven by an aging population, sedentary lifestyles, and increasing healthcare spending.
  • The Asia Pacific region is the fastest-growing market due to its large patient base and rising healthcare expenditures.
  • Generic versions of telmisartan are increasingly popular, impacting profit margins but offering growth opportunities.
  • Key players are expanding their presence in emerging markets to capitalize on growth potential.
  • Favorable government policies and robust healthcare infrastructure support market growth.

FAQs

Q: What is the projected growth rate of the global telmisartan market from 2024 to 2031? A: The global telmisartan market is expected to grow at a CAGR of 3.7% from 2024 to 2031[4].

Q: Which region is expected to dominate the telmisartan market in the forecast period? A: North America is expected to dominate the market, but the Asia Pacific region is the fastest-growing segment[1][4].

Q: What are the key drivers of the telmisartan market? A: Key drivers include the increasing senior population, sedentary lifestyles, approval of generic versions, and rising healthcare spending[1].

Q: How has the shift to generic drugs impacted the telmisartan market? A: The shift to generic drugs has increased market volume but reduced average selling prices, impacting profit margins[4].

Q: What are the opportunities for telmisartan market players in emerging markets? A: Emerging markets offer opportunities due to large patient bases, rising healthcare expenditures, and the growing demand for fixed-dose combinations and generic drugs[4].

Cited Sources

  1. Straits Research: Telmisartan Market Size, Share and Forecast to 2030[1]
  2. OpenPR: Telmisartan Market Segment Size, Growth, and Trends Forecast[2]
  3. Reanin: Telmisartan Market | Growth | Share | Size | Trends and Forecast[3]
  4. Coherent Market Insights: Telmisartan Market - Share, Size and Industry Analysis[4]

More… ↓

⤷  Subscribe

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.